News

Thermo Fisher Posts 3% Q2 Rise
Thermo Fisher Scientific is a global science and diagnostics company serving pharmaceutical, biotechnology, healthcare, academic, and government customers. It is known for instruments, chemicals, and ...
Novo Nordisk's Cardiometabolic Portfolio, Led by Semaglutide, Looks Underappreciated
Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...
The Manila Times13h
First-half 2025 results
Haverhill contributed €14 million in net sales and €3 million in Core EBITDA in H1 2025 consolidated results, compared to €25 ...
Merck Stock Is Almost A Classical Benjamin Graham Investment
Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...
Galderma's Diversified Dermatology Portfolio and Drug Pipeline Position It Well for Long-Term Growth
Galderma is a pure-play dermatology company, with a leadership position in the self-care segment of the market, with more than 90% of total sales paid by consumers out of pocket. Its long-term revenue ...
Taiwan News13h
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
EBITDA(1) of € 496.3 million, +9.6%, margin on revenue of 37.5% Adjusted net income(2) of € 327.8 million, +8.9% Net income of € 216.1 million, -4.1% Free cash flow(4) of € 256.8 million, +€ 0.2 ...
BioSpace1h
Four Scrappy Biotechs Braving the Stormy Market Alone
Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...
Livewire Markets3h
A return to fundamentals
Source: Bloomberg, data from to 31 March 2025 to 30 June 2025. Returns are for the MSCI All Country World Index (ACWI) and its 11 sectors. The MSCI ACWI Index captures large- and mid-cap ...
Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch
Dr. Mates said: "Medincell is entering a new era and I’m excited to help shape its future. Its vision and achievements closely align with my passion for advancing medical innova ...
Triple-Negative Breast Cancer Market Gearing Up For Impressive Growth At A CAGR Of 4.7% During The Forecast Period (2025-2034) Delveinsight
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted th ...
Havas Delivers Solid Performance in the First Half of 2025, With Organic Growth of +2.3%, and Adjusted EBIT up 8.3% Year-on-Year
Net revenue1 of 1,346 million euros, up 2.9%, sustained by organic growth of +2.3% Acceleration in organic growth during the second quarter of ...
DelveInsight Business Research, LLP: Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...